Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 39.19% is 102% above its 5-year average of 19.44%, near the high end of its 5-year range (0.68%–39.19%).
As of the fiscal period ended Wednesday, December 31, 2025. 96.10% above its 12-month average of 19.98%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
39.19%
RETURN ON EQUITY (ROE) AVG TTM
19.98%
RETURN ON EQUITY (ROE) AVG 3Y
21.60%
RETURN ON EQUITY (ROE) AVG 5Y
19.44%
RETURN ON EQUITY (ROE) AVG 10Y
32.53%
RETURN ON EQUITY (ROE) AVG 15Y
29.01%
RETURN ON EQUITY (ROE) AVG 20Y
33.99%
CURRENT VS TTM AVG
+96.10%
CURRENT VS 3Y AVG
+81.44%
CURRENT VS 5Y AVG
+101.61%
CURRENT VS 10Y AVG
+20.46%
CURRENT VS 15Y AVG
+35.09%
CURRENT VS 20Y AVG
+15.28%
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+259.87%
vs the sector median at left
Gilead Sciences, Inc.
Market Cap
$160.55B
Return on Equity (ROE)
39.19%
TTM Avg
19.98%
3Y Avg
21.60%
5Y Avg
19.44%
Market Cap
$179.58B
Return on Equity (ROE)
10.42%
TTM Avg
20.32%
3Y Avg
18.59%
5Y Avg
17.97%
Market Cap
$139.86B
Return on Equity (ROE)
8.31%
TTM Avg
9.04%
3Y Avg
13.32%
5Y Avg
16.07%
Market Cap
$137.47B
Return on Equity (ROE)
3.79%
TTM Avg
4.23%
3Y Avg
6.35%
5Y Avg
7.74%
Market Cap
$134.62B
Return on Equity (ROE)
7.61%
TTM Avg
7.38%
3Y Avg
9.51%
5Y Avg
10.24%
Market Cap
$126.79B
Return on Equity (ROE)
36.25%
TTM Avg
-8.30%
3Y Avg
7.76%
5Y Avg
4.45%
Market Cap
$126.60B
Return on Equity (ROE)
14.52%
TTM Avg
14.50%
3Y Avg
15.05%
5Y Avg
14.30%
Market Cap
$121.16B
Return on Equity (ROE)
22.41%
TTM Avg
8.96%
3Y Avg
15.60%
5Y Avg
19.47%
Market Cap
$119.23B
Return on Equity (ROE)
17.28%
TTM Avg
15.07%
3Y Avg
13.91%
5Y Avg
13.46%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. (GILD) | $160.55B | 39.19% | 19.98% | 21.60% | 19.44% |
| Abbott Laboratories (ABT)vs › | $179.58B | 10.42% | 20.32% | 18.59% | 17.97% |
| Pfizer Inc. (PFE)vs › | $139.86B | 8.31% | 9.04% | 13.32% | 16.07% |
| CVS Health Corp. (CVS)vs › | $137.47B | 3.79% | 4.23% | 6.35% | 7.74% |
| Danaher Corporation (DHR)vs › | $134.62B | 7.61% | 7.38% | 9.51% | 10.24% |
| Bristol-Myers Squibb Company (BMY)vs › | $126.79B | 36.25% | -8.30% | 7.76% | 4.45% |
| Stryker Corporation (SYK)vs › | $126.60B | 14.52% | 14.50% | 15.05% | 14.30% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $121.16B | 22.41% | 8.96% | 15.60% | 19.47% |
| Intuitive Surgical, Inc. (ISRG)vs › | $119.23B | 17.28% | 15.07% | 13.91% | 13.46% |
| Amgen Inc. (AMGN)vs › | $202.95B | 84.87% | 79.33% | 111.35% | 101.76% |
ROE
39.2%
ROA
16.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 37.49% |
| 2024-12-31 | 2.48% |
| 2023-12-31 | 24.81% |
| 2022-12-31 | 21.62% |
| 2021-12-31 | 29.55% |
| 2020-12-31 | 0.68% |
| 2019-12-31 | 23.91% |
| 2018-12-31 | 25.51% |
| 2017-12-31 | 22.64% |
| 2016-12-31 | 71.48% |
| 2015-12-31 | 97.70% |
| 2014-12-31 | 78.45% |
| 2013-12-31 | 27.04% |
| 2012-12-31 | 27.86% |
| 2011-12-31 | 41.60% |
| 2010-12-31 | 49.48% |
| 2009-12-31 | 41.40% |
| 2008-12-31 | 46.32% |
| 2007-12-31 | 46.69% |
| 2006-12-31 | -65.54% |
| 2005-12-31 | 26.88% |
| 2004-12-31 | 24.02% |
| 2003-12-31 | -7.18% |
| 2002-12-31 | 12.62% |
| 2001-12-31 | 11.55% |
| 2000-12-31 | -16.17% |
| 1999-12-31 | -22.37% |
| 1998-12-31 | -13.43% |
| 1997-12-31 | -22.98% |
| 1996-12-31 | -7.44% |
